Kyriakos Amarantidis

Author

Democritus University of Thrace

Also Known As

Amarantidis K, K Amarantidis, K. Amarantidis, KYRIAKOS AMARANTIDIS, Kyriakos Amarantidis

Publications

510

Citations

H-Index

Concepts

All Affiliations

Democritus University of Thrace University Hospital of Alexandroupolis National and Kapodistrian University of Athens

About

Kyriakos Amarantidis is an author at Democritus University of Thrace specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	137
2	Health Sciences	1	1	47
3	Cell Biology	1	1	75
4	Hepatology	1	1	47
5	Pathology	1	1	75

Kyriakos Amarantidis

Publications

384

Citations

H-Index

Page 1

	Year	Citations
Transtympanic Injections of N-acetylcysteine for the Prevention of Cisplatin-induced Ototoxicity Maria Riga, Leonidas Chelis, Stylianos Kakolyris, American Journal of Clinical Oncology	2011	108
Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients Ioanna Balgkouranidou, Dimitrios Matthaios, Anastasios J. Karayiannakis, Mutation research. Fundamental and molecular mechanisms of mutagenesis OncologyPrognostic RoleGastrointestinal OncologyMedicinePathology	2015	75
Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer Dimitrios Matthaios, Ioanna Balgkouranidou, Anastasios J. Karayiannakis, Oncology Letters	2016	55
Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Michael Mantatzis, Stylianos Kakolyris, Kyriakos Amarantidis, European Radiology HepatologyMedical ImagingLiver Metastatic DiseaseMedicineHepatobiliary Tumor	2009	47
Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients Evangelos Karamitrousis, Ioanna Balgkouranidou, Nikolaos Xenidis, Technology in Cancer Research & Treatment	2021	27
Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer Kyriakos Amarantidis, Nikolaos Xenidis, Leonidas Chelis, Oncology	2011	20
Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal Cancer Antonia Cheretaki, Makrina Karaglani, Ioanna Balgkouranidou, Journal of Clinical Medicine	2021	16
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study Nikolaos Xenidis, Leonidas Chelis, Kyriakos Amarantidis, Cancer Chemotherapy and Pharmacology Pancreatic CancerGastrointestinal OncologyMedicinePhase Ii StudySurgery	2011	15
Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece Georgia Ragia, Anthi Maslarinou, Natalia Atzemian, Frontiers in Pharmacology	2023	11
Gender-Dependent Association of <i>Tyms</i> -TSER Polymorphism With 5-Fluorouracil or Capecitabine-Based Chemotherapy Toxicity Charalampia Ioannou, Georgia Ragia, Ioanna Balgkouranidou, Pharmacogenomics	2021	10

Page 1